FDA Greenlights Easier Path for Scar-Reducing Light Therapy Devices
Published Date: 5/1/2026
Rule
Summary
The FDA is officially classifying phototherapy devices that help reduce the look of fresh surgical cuts as Class II, meaning they have special safety rules but are easier to get to patients. This change, effective May 1, 2026, makes it safer and simpler for companies to offer these devices without the toughest regulations. Patients and makers both win with better access and less red tape!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Device moved to Class II, easier market access
The FDA officially classified phototherapy devices for reducing the appearance of acute post-surgical incisions as Class II (special controls), effective May 1, 2026, with the classification applicable December 3, 2021. This puts the device in a lower regulatory class than automatic Class III and lets sponsors rely on the De Novo/510(k) pathway and enables the device to serve as a predicate for future 510(k) devices.
Manufacturers must meet special testing and labeling
To fall within Class II, manufacturers must meet special controls including non-clinical performance testing (spectrum and power verification, heat dissipation, biophotonic properties), biocompatibility and sterility testing, shelf-life demonstration for the photoconverter gel, electromagnetic/electrical/thermal safety testing, software verification/validation and hazard analysis, and specific labeling (technical specs, eye-safety warnings, and gel shelf life). These requirements are codified at 21 CFR 878.4880.
Patients may see improved access to device
FDA states that classifying these phototherapy devices into Class II will enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens. The final order is effective May 1, 2026, and the device type was classified December 3, 2021.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
Previous / Next Documents
Previous: 2026-08494 — Small Business Lending Under the Equal Credit Opportunity Act (Regulation B)
Starting June 30, 2026, new rules will help banks and lenders better track loans to small, women-owned, and minority-owned businesses. These changes make it easier for lenders to follow the rules, improve the quality of loan data, and support fair lending. Lenders must fully comply by January 1, 2028, so small businesses get a fair shot at credit.
Next: 2026-08515 — Overweight and Oversize Items Fee Application
Starting July 12, 2026, the Postal Service will charge a $200 fee for overweight or oversize items found in the mail system or reported in shipping manifests. This fee applies to both retail and commercial mailers, except for items caught and returned during retail transactions. Mailers must pay the fee before their item is released, so watch your package size and weight!